Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-7: axicabtagene ciloleucel versus standard second-line care in relapsed or refractory large B-cell lymphoma
NL-OMON52520Phase 3Completed
- Sponsor
- Kite Pharma
- Start
- Jun 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, follicular lymphoma, transformed (t-FL) and 4 more comparing Axicabtagene ciloleucel arm with Standard of care arm (2 arms). Primary endpoint: Event-free survival. Started Jun 2018; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma, transformed (t-FL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)diffuse large B-cell lymphoma associated with chronic inflammation (DLBCL-CI)
Beyond the preview
Go deeper on NL-OMON52520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52520.